ALNY
$165.04+5.36%
as of close, Nov 13, 2026
☾ AH $165.04 +5.36%
Head-to-head:Compare with VRTX or any ticker →
Alnylam Pharmaceuticals Inc. monthly returns
Alnylam Pharmaceuticals Inc. has averaged 2.36% a month with dividends reinvested, and risen in 53% of months, through November 13, 2026. The table lists the most recent months; the chart, the last 5 years.
Average month
+2.4%
269 months
Best month
+63.7%
Jun 2024
Worst month
-47.5%
Oct 2016
Positive months
53%
of all months
Month by month#
Data provided bySource: Twelve Data| Month | Path | Total return |
|---|---|---|
| Nov 2026 | +0.0% | |
| Oct 2026 | -33.1% | |
| Sep 2026 | +2.5% | |
| Aug 2026 | +17.1% | |
| Jul 2026 | -31.7% | |
| Jun 2026 | -0.3% | |
| May 2026 | -2.4% | |
| Apr 2026 | -6.5% | |
| Mar 2026 | -0.6% | |
| Feb 2026 | -1.5% | |
| Jan 2026 | -15.0% | |
| Dec 2025 | -11.9% | |
| Nov 2025 | -1.1% | |
| Oct 2025 | +0.0% | |
| Sep 2025 | +2.1% | |
| Aug 2025 | +13.8% | |
| Jul 2025 | +20.3% | |
| Jun 2025 | +7.1% | |
| May 2025 | +15.7% | |
| Apr 2025 | -2.5% | |
| Mar 2025 | +9.4% | |
| Feb 2025 | -9.1% | |
| Jan 2025 | +15.3% | |
| Dec 2024 | -7.0% | |
| Nov 2024 | -5.1% | |
| Oct 2024 | -3.1% | |
| Sep 2024 | +4.7% | |
| Aug 2024 | +10.6% | |
| Jul 2024 | -2.3% | |
| Jun 2024 | +63.7% | |
| May 2024 | +3.1% | |
| Apr 2024 | -3.7% | |
| Mar 2024 | -1.1% | |
| Feb 2024 | -12.6% | |
| Jan 2024 | -9.7% | |
| Dec 2023 | +13.8% | |
| Nov 2023 | +10.8% | |
| Oct 2023 | -14.3% | |
| Sep 2023 | -10.5% | |
| Aug 2023 | +1.2% | |
| Jul 2023 | +2.9% | |
| Jun 2023 | +2.7% | |
| May 2023 | -7.1% | |
| Apr 2023 | -0.6% | |
| Mar 2023 | +4.6% | |
| Feb 2023 | -15.4% | |
| Jan 2023 | -4.7% | |
| Dec 2022 | +7.7% | |
| Nov 2022 | +6.4% | |
| Oct 2022 | +3.5% | |
| Sep 2022 | -3.1% | |
| Aug 2022 | +45.5% | |
| Jul 2022 | -2.6% | |
| Jun 2022 | +15.9% | |
| May 2022 | -5.7% | |
| Apr 2022 | -18.3% | |
| Mar 2022 | +3.4% | |
| Feb 2022 | +14.7% | |
| Jan 2022 | -18.9% | |
| Dec 2021 | -7.7% | |
| Nov 2021 | +15.2% | |
| Oct 2021 | -15.5% | |
| Sep 2021 | -6.3% | |
| Aug 2021 | +12.6% | |
| Jul 2021 | +5.6% | |
| Jun 2021 | +19.4% | |
| May 2021 | +1.0% | |
| Apr 2021 | -0.4% | |
| Mar 2021 | -4.7% | |
| Feb 2021 | -1.6% | |
| Jan 2021 | +15.8% | |
| Dec 2020 | +0.0% | |
| Nov 2020 | +5.6% | |
| Oct 2020 | -15.5% | |
| Sep 2020 | +9.8% | |
| Aug 2020 | -9.0% | |
| Jul 2020 | -1.6% | |
| Jun 2020 | +9.5% | |
| May 2020 | +2.7% | |
| Apr 2020 | +21.0% | |
| Mar 2020 | -7.5% | |
| Feb 2020 | +2.5% | |
| Jan 2020 | -0.3% | |
| Dec 2019 | -1.7% | |
| Nov 2019 | +35.0% | |
| Oct 2019 | +7.9% | |
| Sep 2019 | -0.3% | |
| Aug 2019 | +4.0% | |
| Jul 2019 | +6.9% | |
| Jun 2019 | +7.5% | |
| May 2019 | -24.4% | |
| Apr 2019 | -4.4% | |
| Mar 2019 | +9.9% | |
| Feb 2019 | +1.8% | |
| Jan 2019 | +14.6% | |
| Dec 2018 | -10.2% | |
| Nov 2018 | +0.9% | |
| Oct 2018 | -8.1% | |
| Sep 2018 | -28.7% | |
| Aug 2018 | +29.1% | |
| Jul 2018 | -3.5% | |
| Jun 2018 | -1.0% | |
| May 2018 | +5.2% | |
| Apr 2018 | -20.6% | |
| Mar 2018 | -0.9% | |
| Feb 2018 | -7.6% | |
| Jan 2018 | +2.3% | |
| Dec 2017 | -5.6% | |
| Nov 2017 | +10.4% | |
| Oct 2017 | +3.7% | |
| Sep 2017 | +37.0% | |
| Aug 2017 | +3.6% | |
| Jul 2017 | +3.7% | |
| Jun 2017 | +21.8% | |
| May 2017 | +22.1% | |
| Apr 2017 | +4.6% | |
| Mar 2017 | -0.8% | |
| Feb 2017 | +29.1% | |
| Jan 2017 | +6.8% | |
| Dec 2016 | -14.7% |
Monthly total return (since Dec 2021)#
−100%−50%0%50%100%
Dec 2021-7.7%
Jan 2022-19%
Feb 2022+15%
Mar 2022+3.4%
Apr 2022-18%
May 2022-5.7%
Jun 2022+16%
Jul 2022-2.6%
Aug 2022+46%
Sep 2022-3.1%
Oct 2022+3.5%
Nov 2022+6.4%
Dec 2022+7.7%
Jan 2023-4.7%
Feb 2023-15%
Mar 2023+4.6%
Apr 2023-0.56%
May 2023-7.1%
Jun 2023+2.7%
Jul 2023+2.9%
Aug 2023+1.2%
Sep 2023-10%
Oct 2023-14%
Nov 2023+11%
Dec 2023+14%
Jan 2024-9.7%
Feb 2024-13%
Mar 2024-1.1%
Apr 2024-3.7%
May 2024+3.1%
Jun 2024+64%
Jul 2024-2.3%
Aug 2024+11%
Sep 2024+4.7%
Oct 2024-3.1%
Nov 2024-5.1%
Dec 2024-7.0%
Jan 2025+15%
Feb 2025-9.1%
Mar 2025+9.4%
Apr 2025-2.5%
May 2025+16%
Jun 2025+7.1%
Jul 2025+20%
Aug 2025+14%
Sep 2025+2.1%
Oct 2025+0.01%
Nov 2025-1.1%
Dec 2025-12%
Jan 2026-15%
Feb 2026-1.5%
Mar 2026-0.62%
Apr 2026-6.5%
May 2026-2.4%
Jun 2026-0.31%
Jul 2026-32%
Aug 2026+17%
Sep 2026+2.5%
Oct 2026-33%
Nov 2026+0.02%
20222022Jul2023Jul2024Jul2025Jul2026JulAlnylam Pharmaceuticals Inc. returns by calendar month#
Every month of every year since 2004, one tick per year on a shared scale; the dark bar is the month's average. Total returns, dividends reinvested.
November 2026 so far: +0.02% — 17th of 23 Novembers since 2004 at the last close; the average November returned +7.8%.
| Month | −65%0+65% | Average | Median | Up | Best | Worst |
|---|---|---|---|---|---|---|
| Jan | +2.9% | +0.3% | 50% | +41.8% 2012 | -26.8% 2016 | |
| Feb | +0.3% | -1.6% | 45% | +29.1% 2017 | -15.4% 2023 | |
| Mar | -1.3% | -0.7% | 45% | +9.9% 2019 | -17.4% 2014 | |
| Apr | -2.2% | -1.1% | 36% | +21.0% 2020 | -26.2% 2014 | |
| May | +3.8% | +2.4% | 59% | +28.7% 2015 | -24.4% 2019 | |
| Jun | +5.3% | +2.3% | 59% | +63.7% 2024 | -22.6% 2016 | |
| Jul | +8.9% | +3.7% | 65% | +60.4% 2012 | -31.9% 2004 | |
| Aug | +4.3% | +2.6% | 61% | +45.5% 2022 | -25.6% 2011 | |
| Sep | +3.4% | +2.1% | 57% | +40.2% 2007 | -28.7% 2018 | |
| Oct | -5.5% | -8.1% | 39% | +36.8% 2006 | -47.5% 2016 | |
| Nov | +7.8% | +6.3% | 73% | +52.4% 2004 | -30.4% 2010 | |
| Dec | +0.6% | -1.0% | 45% | +35.7% 2008 | -14.7% 2016 |
Methodology#
Monthly returns are total returns (dividends reinvested), computed from ALNY's split- and dividend-adjusted month-end closes. The table shows the most recent 120 months and the bar chart the most recent 60. See the year-by-year returns for the annual view. Past performance does not predict future returns; not investment advice.
FAQ#
- What is Alnylam Pharmaceuticals Inc.'s average monthly return?
- Alnylam Pharmaceuticals Inc. has averaged about 2.36% per month (dividends reinvested), positive in roughly 53% of months. The best month was Jun 2024 (+63.7%) and the worst was Oct 2016 (-47.5%).
More on Alnylam Pharmaceuticals Inc.
By month for: S&P 500 · S&P 500 Equal Weight · US Stock Market · Nasdaq-100
Head-to-head:Compare with VRTX or any ticker →